Breast Carcinoma

  • Fernando SchmittEmail author
  • Ben Davidson


Breast cancer is the most common malignancy (23% of all cancers), with an estimated 1.15 million new cases worldwide in 2002, and is the leading cause of cancer mortality in women (14% of female cancer deaths).1 In the U.S., 61% of new breast cancer cases are diagnosed while localized, 31% are diagnosed in a regional stage, and 6% have already metastasized to distant sites at diagnosis (stage unknown in the remaining 2%).2 Breast cancer metastasizes most often to axillary lymph nodes, but may involve any organ.


Breast Cancer Breast Carcinoma Endometrial Carcinoma Mesothelial Cell Pleural Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.PubMedCrossRefGoogle Scholar
  3. 3.
    Fentiman IS, Millis R, Sexton S, Hayward JL. Pleural effusion in breast cancer: a review of 105 cases. Cancer. 1981;47:2087-2092.PubMedCrossRefGoogle Scholar
  4. 4.
    Raju RN, Kardinal CG. Pleural effusion in breast carcinoma: analysis of 122 cases. Cancer. 1981;48:2524-2527.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute. Cancer. 1995;76:1377-1387.PubMedCrossRefGoogle Scholar
  6. 6.
    Buck M, Ingle JN, Giuliani ER, Gordon JR, Therneau TM. Pericardial effusion in women with breast cancer. Cancer. 1987;60:263-269.PubMedCrossRefGoogle Scholar
  7. 7.
    DiBonito L, Falconieri G, Colautti I, Bonifacio D, Dudine S. The positive peritoneal effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol. 1993;37:483-488.PubMedGoogle Scholar
  8. 8.
    Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985;56:905-909.PubMedCrossRefGoogle Scholar
  9. 9.
    Pokieser W, Cassik P, Fischer G, Vesely M, Ulrich W, Peters-Engl C. Malignant pleural and pericardial effusion in invasive breast cancer: impact of the site of the primary tumor. Breast Cancer Res Treat. 2004;83:139-142.PubMedCrossRefGoogle Scholar
  10. 10.
    Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer. 1988;62:2226-2233.PubMedCrossRefGoogle Scholar
  11. 11.
    DeCamp MM Jr, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest. 1997;112(4 Suppl):291S-295S.PubMedCrossRefGoogle Scholar
  12. 12.
    Geisinger KR, Stanley MW, Raab SS, Silverman JF, Abati A, eds. Modern Cytopathology. Philadelphia: Churchill Livingstone; 2004.Google Scholar
  13. 13.
    Bedrossian CWM. Malignant Effusions. A Multimodal Approach to Cytologic Diagnosis. New York: Igaku-Shoin; 1994.Google Scholar
  14. 14.
    Shidham VB, Atkinson BF. Cytopathologic Diagnosis of Serous Fluids. London: Elsevier; 2007.Google Scholar
  15. 15.
    Naylor B. Pleural, peritoneal and pericardial effusions. In: Bibbo M, Wilbur D, eds. Comprehensive Cytopathology. Philadelphia: Elsevier; 2008:515-578.CrossRefGoogle Scholar
  16. 16.
    Shidham VB, Falzon M. Serous effusions. In: Gray W, Kocjan G, eds. Diagnostic Cytopathology. London: Churchill Livingstone; 2010:115-178.CrossRefGoogle Scholar
  17. 17.
    Rappa G, Lorico A. Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line. Exp Cell Res. 2010;316:1576-1586.PubMedCrossRefGoogle Scholar
  18. 18.
    Danner DE, Gmelich JT. A comparative study of tumor cells from metastatic carcinoma of the breast in effusions. Acta Cytol. 1975;19:509-518.PubMedGoogle Scholar
  19. 19.
    Goldberg S, Rey G, Luce D, et al. Possible effect of environmental exposure to asbestos on geographical variation in mesothelioma rates. Occup Environ Med. 2010;67:417-421.PubMedCrossRefGoogle Scholar
  20. 20.
    Pai RK, West RB. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. Appl Immunohistochem Mol Morphol. 2009;17:202-206.PubMedCrossRefGoogle Scholar
  21. 21.
    Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688-694.PubMedCrossRefGoogle Scholar
  22. 22.
    Wang Z, Spaulding B, Sienko A, et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol. 2009;2:384-389.PubMedGoogle Scholar
  23. 23.
    Ferro P, Franceschini MC, Bacigalupo B, et al. Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR: association with clinical prognostic factors. Anticancer Res. 2010;30:2377-2382.PubMedGoogle Scholar
  24. 24.
    Yan Z, Gidley J, Horton D, Roberson J, Eltoum IE, Chhieng DC. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Diagn Cytopathol. 2009;37:475-478.PubMedCrossRefGoogle Scholar
  25. 25.
    Roncella S, Ferro P, Franceschini MC, et al. Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker mammaglobin. Diagn Mol Pathol. 2010;19:92-98.PubMedCrossRefGoogle Scholar
  26. 26.
    Wang LJ, Greaves WO, Sabo E, et al. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol. 2009;17:505-511.PubMedCrossRefGoogle Scholar
  27. 27.
    Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23:654-661.PubMedCrossRefGoogle Scholar
  28. 28.
    Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg. 2002;73:403-405.PubMedCrossRefGoogle Scholar
  29. 29.
    Schlüter B, Gerhards R, Strumberg D, Voigtmann R. Combined detection of HER2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010;136:1389-1400.PubMedCrossRefGoogle Scholar
  30. 30.
    Davidson B, Konstantinovsky S, Nielsen S, et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients- a novel model for tumor progression. Clin Cancer Res. 2004;10:7335-7346.PubMedCrossRefGoogle Scholar
  31. 31.
    Konstantinovsky S, Smith Y, Zilber S, Tuft Stavnes H, Becker AM, Nesland JM, Reich R, Davidson B. Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol 2010; 2010:969084.Google Scholar
  32. 32.
    Davidson B, Dong HP, Holth A, Berner A, Risberg B. The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions. Breast J. 2008;14:476-482.PubMedCrossRefGoogle Scholar
  33. 33.
    Davidson B, Konstantinovsky S, Kleinberg L, et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol. 2006;102:453-461.PubMedCrossRefGoogle Scholar
  34. 34.
    Yuan Y, Leszczynska M, Konstantinovsky S, Trope’ CG, Reich R, Davidson B. Netrin 4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors. Diagn Cytopathol. 2011;39:562-566.Google Scholar
  35. 35.
    Davidson B, Tuft Stavnes H, Holth A, Chen X, Yang Y, Shih IeM, Wang TL. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med. 2011;15:535-544.Google Scholar
  36. 36.
    Davidson B, Stavnes HT, Nesland JM, Wohlschlaeger J, Yang Y, Shih IeM, Wang TL. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. In press, Hum Pathol.Google Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.IPATIMUP and Medical FacultyPorto UniversityPortoPortugal
  2. 2.Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, The Medical FacultyUniversity of OsloOsloNorway

Personalised recommendations